Legis Daily

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019

USA116th CongressHR-4640| House 
| Updated: 10/14/2019
Peter A. DeFazio

Peter A. DeFazio

Democratic Representative

Oregon

Cosponsors (11)
Marcy Kaptur (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Ro Khanna (Democratic)Janice D. Schakowsky (Democratic)Peter Welch (Democratic)Jesús G. "Chuy" García (Democratic)Lloyd Doggett (Democratic)Chellie Pingree (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 11, 2019
Introduced in House
Oct 11, 2019
Referred to the House Committee on Energy and Commerce.
Oct 14, 2019
Referred to the Subcommittee on Health.
  • October 11, 2019
    Introduced in House
  • October 11, 2019
    Referred to the House Committee on Energy and Commerce.
  • October 14, 2019
    Referred to the Subcommittee on Health.

Health

Drug safety, medical device, and laboratory regulationHealth programs administration and fundingHealth technology, devices, suppliesInflation and pricesIntellectual propertyMedical researchResearch and development

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019

USA116th CongressHR-4640| House 
| Updated: 10/14/2019
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 11, 2019
Introduced in House
Oct 11, 2019
Referred to the House Committee on Energy and Commerce.
Oct 14, 2019
Referred to the Subcommittee on Health.
  • October 11, 2019
    Introduced in House
  • October 11, 2019
    Referred to the House Committee on Energy and Commerce.
  • October 14, 2019
    Referred to the Subcommittee on Health.
Peter A. DeFazio

Peter A. DeFazio

Democratic Representative

Oregon

Cosponsors (11)
Marcy Kaptur (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Ro Khanna (Democratic)Janice D. Schakowsky (Democratic)Peter Welch (Democratic)Jesús G. "Chuy" García (Democratic)Lloyd Doggett (Democratic)Chellie Pingree (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug safety, medical device, and laboratory regulationHealth programs administration and fundingHealth technology, devices, suppliesInflation and pricesIntellectual propertyMedical researchResearch and development